• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

何为公平?美国和澳大利亚处方药获取方面的选择、公平性与透明度。

What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia.

作者信息

Lopert Ruth, Rosenbaum Sara

机构信息

Australian Department of Health and Ageing.

出版信息

J Law Med Ethics. 2007 Winter;35(4):643-56, 512-3. doi: 10.1111/j.1748-720X.2007.00187.x.

DOI:10.1111/j.1748-720X.2007.00187.x
PMID:18076515
Abstract

The importance of prescription drugs to modern medical practice, coupled with their increasing costs, has strengthened imperatives for national health policies that ensure safety and quality, facilitate affordable access, and promote rational use. Australia has made universal and affordable prescription drug coverage a priority for decades, within a policy framework that emphasizes equity and increasing transparency in coverage design and payment decisions. By contrast, the U.S. lacks such a national policy. Furthermore, federal Medicare reforms aimed at making appropriate drug coverage affordable and accessible employs two icons of the U.S. perception of fairness--the right to choose and the right to challenge coverage design limits--that mask the limited nature of the assistance. As the U.S. seeks to impose its values and priorities on other nations through the negotiation of bilateral and regional trade agreements, it becomes important to consider the two national experiences, in order to avoid trading illusory notions of fairness for true population equity.

摘要

处方药对现代医疗实践至关重要,再加上其成本不断攀升,这强化了制定国家卫生政策的必要性,这些政策要确保药品安全和质量,促进人们能够负担得起并合理使用。几十年来,澳大利亚一直将全民且负担得起的处方药覆盖作为优先事项,其政策框架强调公平以及在覆盖范围设计和支付决策方面提高透明度。相比之下,美国缺乏这样一项国家政策。此外,旨在使适当的药品覆盖变得可负担得起且可及的联邦医疗保险改革采用了美国所认为的公平的两个标志——选择的权利和对覆盖范围设计限制提出质疑的权利——而这掩盖了援助的有限性。由于美国试图通过双边和区域贸易协定谈判将其价值观和优先事项强加于其他国家,因此考虑这两个国家的经验就变得很重要,以便避免用虚幻的公平观念换取真正的人群公平。

相似文献

1
What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia.何为公平?美国和澳大利亚处方药获取方面的选择、公平性与透明度。
J Law Med Ethics. 2007 Winter;35(4):643-56, 512-3. doi: 10.1111/j.1748-720X.2007.00187.x.
2
Pharmaceuticals and medical devices: Medicare Part D. Issue brief.药品和医疗器械:医疗保险D部分。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.
3
Pharmaceuticals and medical devices: Medicare Part D.药品和医疗器械:医疗保险D部分。
Issue Brief Health Policy Track Serv. 2012 Jan 3:1-37.
4
PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.PDP 还是 MA-PD?CMS 第 25 区的医疗保险部分 D 注册决策。
Res Social Adm Pharm. 2010 Jun;6(2):130-42. doi: 10.1016/j.sapharm.2010.04.002.
5
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.《跨太平洋伙伴关系协定如何损害 PHARMAC 并威胁新西兰平价药品的可及性和医疗公平性》
Health Policy. 2013 Oct;112(3):227-33. doi: 10.1016/j.healthpol.2013.07.021. Epub 2013 Aug 30.
6
Impact of cost sharing on prescription drugs used by Medicare beneficiaries.医疗保险受益人的处方药费用分担的影响。
Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.
7
Assessing the impact of coverage gaps in the Medicare Part D drug benefit.评估医疗保险D部分药物福利覆盖缺口的影响。
Find Brief. 2008 Apr;11(3):1-3.
8
The high price of "free" trade: U.S. trade agreements and access to medicines.“免费”贸易的高昂代价:美国贸易协定与药品可及性
J Law Med Ethics. 2013 Spring;41(1):199-223. doi: 10.1111/jlme.12014.
9
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.药品和医疗器械:医疗保险D部分。年终问题简报。
Issue Brief Health Policy Track Serv. 2009 Jan 5:1-26.
10
Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.与独立药房所有者对医疗保险处方药部分合同满意度相关的因素。
Res Social Adm Pharm. 2010 Jun;6(2):121-9. doi: 10.1016/j.sapharm.2010.03.004. Epub 2010 May 7.

引用本文的文献

1
Assessment of the therapeutic value of new medicines marketed in Australia.对在澳大利亚上市的新药的治疗价值评估。
J Pharm Policy Pract. 2013 Jun 13;6:2. doi: 10.1186/2052-3211-6-2. eCollection 2013.